Prognostic ability of simplified nuclear grading of renal cell carcinoma

Cancer

Volumn 109, Issue 5, 2007, Pages 868-874

  Rioux Leclercq, Nathalie ^a,b,k   Karakiewicz, Pierre I ^c   Trinh, Quoc Dien ^c   Ficarra, Vincenzo ^d   Cindolo, Luca ^e   De La Taille, Alexandre ^f   Tostain, Jacques ^g   Zigeuner, Richard ^h   Mejean, Arnaud ⁱ   Patard, Jean Jacques ^i,j  

^a Rennes Hospital   (France)

^b CNRS   (France)

^c CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^d UNIVERSITY OF VERONA   (Italy)

^e Department of Urology ^*  (Italy)

^f HENRI MONDOR HOSPITAL   (France)

^g UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^h UNIVERSITY HOSPITAL GRAZ   (Austria)

ⁱ Cancer Comity of the French Urologic Association   (France)

^j RENNES UNIVERSITY HOSPITAL   (France)

^k PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Fuhrman grade; Prognostic; RCC; Renal cell carcinoma; Statistic

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CHILD; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; UNIVARIATE ANALYSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, RENAL CELL; CELL NUCLEUS; CHILD; FEMALE; HUMANS; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 33847363254     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22463     Document Type: Article

References (22)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med. 2005;353:2477-2490.
2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med. 1996;335:865-875.
3. Pantuck AJ, Zisman A, Belldegrun AS. The changing natural history of renal cell carcinoma. J Urol. 2001;166:1611-1623.
4. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6:655-663.
5. Ficarra V, Righetti R, Martignoni G, et al. Prognostic value of renal cell carcinoma nuclear grading: multivariate analysis of 333 cases. Urol Int. 2001;67:130-134.
6. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19:1649-1657.
7. Ficarra V, Martignoni G, Maffei N, et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer. 2005;103:68-75.
8. Greene FL, American Joint Committee on Cancer, American Cancer Society. AJCC Cancer Staging Manual. Berlin: Springer.
9. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763-2771.
10. Patard JJ, Leray E, Rodriguez A, Rioux-Leclercq N, Guille F, Lobel B. Correlation between symptom graduation, tumor characteristics and survival in renal cell carcinoma. Eur Urol. 2003;44:226-232.
11. Cheville JC, Lohse CM, Zincke H, Weaver AL, Blute ML. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-624.
12. Patard JJ, Leray E, Cindolo L, et al. Multi-institutional validation of a symptom based classification for renal cell carcinoma. J Urol. 2004;172:858-862.
13. Lane BR, Kattan MW. Predicting outcomes in renal cell carcinoma. Curr Opin Urol. 2005;15:289-297.
14. Ficarra V, Guille F, Schips L, et al. Proposal for revision of the TNM classification system for renal cell carcinoma. Cancer. 2005;104:2116-2123.
15. Kattan MW. Judging new markers by their ability to improve predictive accuracy. J Natl Cancer Inst. 2003;95:634-635.
16. Bretheau D, Lechevallier E, de Fromont M, Sault MC, Rampal M, Coulange C. Prognostic value of nuclear grade of renal cell carcinoma. Cancer. 1995;76:2543-2549.
17. Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer. 1988;61:1639-1651.
18. Bleumer I, Oosterwijk E, De Mulder P Mulders PF. Immunotherapy for renal cell carcinoma. Eur Urol. 2003;44:65-75.
19. Ravaud A, Delva R, Gomez F, et al. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter phase II trial from the Groupe Francais d'Immunotherapie. Cancer. 2002;95:2324-2330.
20. Lang H, Lindner V, de Fromont M, et al. Multicenter determination of optimal interobserver agreement using the Fuhrman grading system for renal cell carcinoma: assessment of 241 patients with >15-year follow-up. Cancer. 2005;103:625-629.
21. Lanigan D, Conroy R, Barry-Walsh C, Loftus B, Royston D, Leader M. A comparative analysis of grading systems in renal adenocarcinoma. Histopathology. 1994;24:473-476.
22. Al-Aynati M, Chen V, Salama S, Shuhaibar H, Treleaven D, Vincic L. Interobserver and intraobserver variability using the Fuhrman grading system for renal cell carcinoma. Arch Pathol Lab Med. 2003;127:593-596.